hVIVO PLC Director dealings (6156C)
14 June 2023 - 5:00PM
UK Regulatory
TIDMHVO
RNS Number : 6156C
hVIVO PLC
14 June 2023
hVIVO plc
("hVIVO" or the "Company")
Director dealings
hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc)
announces that it has received notification that Yamin 'Mo' Khan,
Chief Executive Officer of the Company, yesterday acquired 13,526
ordinary shares of 0.1 pence each in the capital of the Company as
a result of a dividend reinvestment plan. Following the purchase of
shares Mo holds 523,730 ordinary shares representing approximately
0.08 per cent of the Company's issued ordinary capital.
For further information please contact:
hVIVO plc +44 (0) 20 7756 1300
Yamin 'Mo' Khan, Chief Executive
Officer
Stephen Pinkerton, Chief Financial
Officer
Liberum Capital (Nominated Adviser and
Joint Broker) +44 (0) 20 3100 2000
Ben Cryer, Edward Mansfield, Phil Walker,
Will King
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash, Charlie Beeson, Nigel Birks,
Harriet Ward (ECM)
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0) 1 679 6363
Anthony Farrell, Niall Gilchrist
Walbrook PR (Financial PR & IR) +44 (0) 20 7933 8780 or hvivo@walbrookpr.com
Stephanie Cuthbert / Phillip +44 (0) 7796 794 663 / +44 (0) 7867 984
Marriage / 082 /
Louis Ashe-Jepson +44 (0) 7747 515 393
Notes to Editors
About hVIVO
hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly
growing specialist contract research organisation (CRO) and the
world leader in testing infectious and respiratory disease vaccines
and therapeutics using human challenge clinical trials. The Group
provides end-to-end early clinical development services to its
large, established and growing repeat client base, which includes
four of the top 10 largest global biopharma companies.
The Group's fast-growing services business includes a unique
portfolio of 11 human challenge models, with a number of new models
under development, to test a broad range of infectious and
respiratory disease products. The Company has world class challenge
agent manufacturing, specialist drug development and clinical
consultancy services via its Venn Life Sciences brand, and a lab
offering via its hLAB brand, which includes virology, immunology
biomarker and molecular testing. The Group offers additional
clinical field trial services such as patient recruitment and
clinical trial site services.
hVIVO runs challenge studies in London from its Whitechapel
quarantine clinic, its state-of-the-art QMB clinic with its highly
specialised on-site virology and immunology laboratory, and its
clinic in Plumbers Row. To recruit volunteers / patients for its
studies, the Company leverages its unique clinical trial
recruitment capability via its FluCamp volunteer screening
facilities in London and Manchester.
Notification of transactions by Directors, Persons Discharging
Managerial Responsibilities ("PDMRs") and persons closely
associated with them.
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Yamin Khan
------------------------------- -------------------------------------
2. Reason for the Notification
----------------------------------------------------------------------
a) Position/status Chief E xecutive Officer
------------------------------- -------------------------------------
b) Initial notification/amendment Initial notification
------------------------------- -------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name hVIVO plc
------------------------------- -------------------------------------
b) LEI 213800VT5KBM7JLIV118
------------------------------- -------------------------------------
4. Details of the transaction(s):section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv)each place where transactions have been
conducted
----------------------------------------------------------------------
a) Description of the Financial Ordinary shares of 0.1 pence each
instrument, type of
instrument
------------------------------- -------------------------------------
Identification code ESVUFR
ISIN GB00B9275X97
------------------------------- -------------------------------------
b) Nature of the Transaction Purchase of ordinary shares pursuant
to a dividend reinvestment plan
------------------------------- -------------------------------------
c) Price(s) and volume(s) Price Volume
16.97 pence 13,526
-------
------------------------------- -------------------------------------
d) Aggregated information As above
- Aggregated volume
- Price
------------------------------- -------------------------------------
e) Date of the transaction 13/06/2023
------------------------------- -------------------------------------
f) Place of the transaction London Stock Exchange
------------------------------- -------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFZGMVLFKGFZM
(END) Dow Jones Newswires
June 14, 2023 03:00 ET (07:00 GMT)
hVIVO (AQSE:HVO.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024
hVIVO (AQSE:HVO.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024
